Search results

Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.

Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country

The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

Home What NICE does Digital health...

Tools for building or evaluating a medtech evidence base with NICE

Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing

Find out which guidance and quality standards are awaiting development

View a complete list of all our guidance, NICE advice and quality standards currently in development

See a complete list of all our guidance and quality standards currently open for consultation

This NICE resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

Our resource planner tool to help you plan for and implement NICE guidance.

We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.

This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

Result type

HealthTech guidance

Published

27 January 2022